NICE recommends bempedoic acid/ezetimibe for hypercholesterolaemia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 1, 2021 Category: Drugs & Pharmacology Source Type: news
First new oral treatment for high cholesterol in a decade approved by NICE
Bempedoic acid has been approved for routine NHS prescribing with ezetimibe to treat primary hypercholesterolaemia or mixed dyslipidaemia when statins are unsuitable. (Source: GP Online News)
Source: GP Online News - April 28, 2021 Category: Primary Care Tags: Clinical News Source Type: news
Roszet (Rosuvastatin and Ezetimibe Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 1, 2021 Category: Drugs & Pharmacology Source Type: news
FDA Approves Roszet (rosuvastatin and ezetimibe) to Reduce LDL-C in Hyperlipidemia and Homozygous Familial Hypercholesterolemia
Morristown, N.J. March 31, 2021 -- Althera Pharmaceuticals, a company focused on heart health, today announced the FDA approval of Roszet (rosuvastatin and ezetimibe) tablets, as an adjunct to diet, for treatment of elevated low-density lipoprotein... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 31, 2021 Category: Drugs & Pharmacology Source Type: news
FDA Approves Althera ’s Roszet (rosuvastatin and ezetimibe) Tablets, a...
Roszet® is indicated for adults with Primary Non-familial Hyperlipidemia and Homozygous Familial Hypercholesterolemia - Roszet is a powerful and affordable way to significantly lower patients’...(PRWeb March 31, 2021)Read the full story at https://www.prweb.com/releases/fda_approves_altheras_roszet_rosuvastatin_and_ezetimibe_tablets_a_new_oral_therapy_for_powerful_cholesterol_reduction/prweb17832549.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 31, 2021 Category: Pharmaceuticals Source Type: news
Nexlizet (Bempedoic acid and Ezetimibe Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 22, 2021 Category: Drugs & Pharmacology Source Type: news
Nexlizet (Bempedoic acid and Ezetimibe Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 4, 2020 Category: Drugs & Pharmacology Source Type: news
FDA Approves Bempedoic Acid-Ezetimibe Combo for ASCVD, HeFH FDA Approves Bempedoic Acid-Ezetimibe Combo for ASCVD, HeFH
The pairing of two LDL-C-lowering agents called Nexlizet is indicated for use on top of statins to help adults with established ASCVD or heterozygous familial hypercholesterolemia reach their goals.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - February 27, 2020 Category: Cardiology Tags: Cardiology News Alert Source Type: news
FDA Approves Nexlizet (bempedoic acid and ezetimibe) to Lower LDL-Cholesterol
ANN ARBOR, Mich., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the U.S. Food and Drug Administration (FDA) approved Nexlizet (bempedoic acid and ezetimibe) tablet, an oral, once-daily, non-statin LDL-Cholesterol... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 26, 2020 Category: Drugs & Pharmacology Source Type: news
FDA Approves Non-Statin Drug That Lowers Cholesterol
TRENTON, N.J. (AP) — U.S. regulators on Friday approved a new type of cholesterol-lowering drug aimed at millions of people who can’t tolerate — or don’t get enough help from — widely used statin pills like Lipitor and Crestor.
The Food and Drug Administration approved Esperion Therapeutics Inc.’s Nexletol for people genetically predisposed to have sky-high cholesterol and people who have heart disease and need to further lower their bad cholesterol. The daily pill is to be taken in conjunction with a healthy diet and the highest statin dose patients can handle, the FDA said.
High LDL, or bad choles...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - February 24, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Syndicated CBSN Boston Cholesterol Statins Source Type: news
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
In this interview with Dr. Lee Hooper we find out more about this new Cochrane review -Omega-3 fatty acids for the primary and secondary prevention of cardiovascular diseaseTell us about this Cochrane ReviewThere is a great deal of public belief in the cardiovascular benefits of omega-3 fats. Intakes of long-chain omega-3 fats in the US are higher from dietary supplements than foods. But public health advice differs across countries. The National Institute for Health and Clinical Excellence in the UK encourages people to eat oily fish intake (the major source of long-chain omega-3 f ats) but discourages supplementatio...
Source: Cochrane News and Events - February 5, 2020 Category: Information Technology Authors: Katie Abbotts Source Type: news
EMA Panel Backs Bempedoic Acid Alone and With Ezetimibe EMA Panel Backs Bempedoic Acid Alone and With Ezetimibe
The CHMP has recommended approval of bempedoic acid (Nilemdo) and the combination of bempedoic acid/ezetimibe (Nustendi) for primary hypercholesterolemia and mixed dyslipidemia.International Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 31, 2020 Category: Cardiology Tags: Cardiology News Alert Source Type: news
High-Intensity Lipid Lowering May Aid Very Elderly After ACS
TUESDAY, Aug. 6, 2019 -- Among patients hospitalized for acute coronary syndrome (ACS), the greatest benefit from simvastatin-ezetimibe compared with simvastatin alone to lower lipid levels was observed in those 75 years of age or older, according... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 6, 2019 Category: Pharmaceuticals Source Type: news
Results of the Pivotal Phase 3 Study of the Bempedoic Acid / Ezetimibe Combination Tablet Published in the European Journal of Preventative Cardiology Demonstrated Significant LDL-C Lowering
Bempedoic acid / ezetimibe fixed dose combination (FDC) tablet is an oral, once-daily ATP citrate lyase (ACL) inhibitor that reduces cholesterol synthesis in the liver
Bempedoic acid / ezetimibe FDC tablet lowered LDL-C by 38% (placebo-corrected) and re... Biopharmaceuticals, Cardiology Daiichi Sankyo, bempedoic acid, ezetimibe, FDC tablet (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 31, 2019 Category: Pharmaceuticals Source Type: news
Jul 26 2019 This Week in Cardiology Jul 26 2019 This Week in Cardiology
CRT in patients with non-LBBB, ezetimibe, lifestyle diseases in the young, end of life care, and diabetes for the cardiologist are the topics John Mandrola, MD discusses in this week ’ s podcasttheheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 26, 2019 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news
